Contract Option Exercises — July 24, 2026

Leidos Holdings subsidiary won a cost-plus-fixed-fee delivery order from NIH National Cancer Institute for Phase 1/2 vaccine trials through 2029, with $36.8M already funded, providing stable long-term revenue visibility.

PTSI's $130.8M firm-fixed-price NASA contract is 78% paid and ends in September 2023, indicating near-complete execution with no follow-on award yet, creating revenue gap risk.

Frequentis USA's time-and-materials contract for APC units is 84% outlayed ($105.1M of $124.6M), signaling strong funding execution and potential for follow-on work through 2027.

Raytheon's non-competed cost-plus-fixed-fee delivery order under the STARS program runs through June 2025, representing only ~$28M annual revenue—immaterial for RTX but signals potential re-compete risk.

PTSI Managed Services has 78% of its $130.8M NASA contract already paid with no follow-on award, indicating high dependency on a single near-complete contract.

All four contracts are civilian (HHS, NASA, FAA), with zero defense contracts in this period, which may reflect Continuing Resolution constraints or delayed DOD option exercises.

Frequentis USA is foreign-owned (Austrian parent), which could face increased scrutiny under CFIUS or new defense authorization provisions affecting foreign-owned contractors.

Leidos Biomedical's $173.3M NIH contract for vaccine trials through 2029 positions Leidos for follow-on health R&D awards as NIH funding for next-generation vaccines remains a priority.

Raytheon's sole-source $113.2M FAA award under the STARS program suggests an entrenched incumbent position that could lead to follow-on sole-source awards for air traffic control modernization.

The absence of defense contracts in this period may indicate a temporary lull; investors should watch for DOD option exercises in subsequent periods, particularly for Leidos and RTX.

Three of four contracts (NASA, FAA x2) involve physical or IT infrastructure at civilian agencies, totaling $368.5M, indicating sustained investment in non-defense federal facilities and air traffic systems.

Leidos Biomedical's $173.3M NIH award with cost-plus pricing and a six-year performance period exemplifies the stable, low-risk revenue profile of health R&D contracts for large-cap government services firms.

{"entity" => "PTSI Managed Services Inc.", "reason" => "NASA contract is 78% paid and ends September 2023; no follow-on award identified.", "trigger" => "New NASA GSFC facility contract award or contract extension announcement"}

{"entity" => "Frequentis USA, Inc.", "reason" => "FAA contract runs through 2027 with high funding certainty; foreign ownership adds regulatory risk.", "trigger" => "CFIUS review or NDAA provision affecting foreign-owned contractors; FAA budget allocation for telecom equipment"}

{"entity" => "Leidos Holdings, Inc.", "reason" => "NIH contract provides long-term revenue visibility; watch for additional funding obligations under the $173.3M delivery order.", "trigger" => "NIH announcement of additional funding obligations or successful vaccine trial outcomes"}

{"entity" => "Raytheon Company (RTX Corp)", "reason" => "Sole-source FAA STARS contract ends June 2025; re-compete or follow-on award will signal incumbent strength.", "trigger" => "FAA STARS program follow-on award or modification announcement"}